Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study
The Study demonstrated that Onco's Technology increased the sensitivity of PTEN-deficient cancer cells to radiation in tumour-bearing mice using HCT116 colorectal cancer (CRC) models to a statistically significant degree compared to radiation alone. PTEN is a crucial tumour suppressor gene that helps regulate cell growth. When PTEN is mutated or lost, as it often is in cancer cells, these cells become more prone to uncontrolled growth and are less able to repair damage. 2 By inhibiting PNKP, which is involved in DNA repair, the Technology was shown in the study to weaken the cancer cells' ability to recover from radiation, making them more vulnerable to treatment. This suggests that further testing is worthwhile to explore whether lower doses of radiation could be used in conjunction with the Technology to achieve similar therapeutic effects with the potential benefit of reducing side effects and minimizing harm to healthy tissue.
Furthermore, the Study explored the broader implications of this approach. By selectively targeting PNKP in PTEN-deficient cells, the Technology aims to focus on the cancer cells' unique vulnerabilities while sparing normal, healthy cells. This strategy is aimed at developing a more precise and effective way to destroy tumours with less collateral damage, leveraging the weaknesses that arise when both PTEN and PNKP functions are disrupted in cancer cells.
' This Study demonstrated that our Technology has the potential to enhance the effectiveness of radiation therapy specifically in PTEN-deficient tumours; we are accordingly excited to continue pursuing studies toward our mission of paving the way for more targeted and less toxic treatment options and moving Onco towards its goal of becoming a leader in oncology. We are most excited about the future possibilities this Technology holds for improving patient outcomes, " said Thomas O'Shaughnessy, CEO of the Company.
About Colorectal Cancer (CRC):
Colorectal cancer ('CRC') is the third most common cancer in Canada 3 and the third most common cause of cancer-related death in both men and women in the United States. 4 It is the leading cause of cancer death among men under 50 and ranks second overall in cancer-related deaths. 5 The global incidence of CRC is expected to reach 3.2 million new cases by 2040, driven by aging populations, growth, and development. 6 In the United States, over half (55%) of CRC cases are linked to lifestyle factors, including poor diet, lack of exercise, excessive alcohol consumption, and smoking. 7 In Canada, approximately 26,300 new cases of CRC were reported in 2019, with 9,500 deaths attributed to the disease, indicating a shift towards diagnoses at more advanced stages. 8
The Company also announces that, it has engaged the services of Venture Liquidity Providers Inc. (business address: 1 McGuire Cres. Uxbridge, Ontario, Canada, L9P 1G7, email: [email protected], website: www.vlpinc.net, telephone: +1 416-891-4349; and contact: John (JC) Cunningham) ('VLP') to provide market making services, commencing immediately. Under its engagement, VLP will trade common shares of the Company on the Canadian Securities Exchange, and all other trading venues on which the Company's securities may be traded, with the objective of maintaining a reasonable market for the Company's common shares.
Under the terms of the engagement, VLP will receive compensation of CAD$5,000 per month, with payment for the initial three (3) months made in advance. The agreement shall continue in force for a period of three (3) months and will automatically renew for successive additional one-month terms unless otherwise terminated in accordance with this agreement. Either party may terminate the agreement with written notice after the initial three-month term. Upon termination, any of the Issuer's prepaid monthly fees in VLP's possession for months in which no trading has occurred will be refunded within 15 business days.
There are no performance factors contained in the engagement and VLP will not receive shares or options as compensation.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
'Thomas O'Shaughnessy'
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Technology, the Company's ability to submit and complete U.S. FDA trials, the ability of VLP to create and maintain a reasonable market for trading of the Company's shares, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as 'will', 'may', 'potential', 'should', 'anticipate', 'expects' and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Technology, the failure to complete U.S. FDA clinical trials, the failure to receive regulatory approval in respect of the Technology, the failure of VLP to create or maintain a reasonable market for trading of the Company's shares, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
20 hours ago
- Miami Herald
Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market ESTERO, FL / ACCESS Newswire / July 22, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced it plans to launch its newsublingual pre-workout supplement, BUZZ BOMB™, at FitCon and FitExpo, two of the largest fitness conventions held annually in Salt Lake City, Utah (August 1-2) and Anaheim, CA, (August 2-3), respectively. Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential. Buzz BOMB™, offered in four flavors, provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue for immediate effect. FitCon: Mountain America ExpoCenter, Salt Lake City, UT on August 1-2, 2025, Located in Sponsor Alley FitCon is an event that brings together fitness enthusiasts, professionals, brands, and influencers in the health and wellness industry with approximately 20,000 attendees and hundreds of exhibitors. BUZZ BOMB™ is one of seven "Gold Sponsors" at FitCon, which provides benefits including samples provided to every attendee, a large booth located along "Sponsor Alley" where all attendees pass through, as well as FitCon website marketing, advertising and communications to attendees, and a liberal exhibiting of Buzz Bomb's distinctive trademark throughout the exhibition. To learn more about FitCon, please visit The FitExpo: Anaheim Convention Center, Anaheim, CA, August 2-3, 2025, Booth #401 FitExpo brings together a diverse range of fitness brands, competitions, and demonstrations to inspire and guide individuals on their fitness journey and is one of the largest fitness conventions in the world with over 33,000 people expected to attend. As a convention sponsor, BUZZ BOMB™ will be provided numerous benefits and support, including: Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Aspire Biopharma Holdings, Inc. Contact PCG AdvisoryKevin McGrath+1-646-418-7002kevin@ SOURCE: Aspire Biopharma Holdings, Inc.
Miami Herald
20 hours ago
- Miami Herald
Viemed Healthcare Announces Second Quarter 2025 Earnings Conference Call Details
LAFAYETTE, LA / ACCESS Newswire / July 22, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, today announced that it will host its Second Quarter 2025 Earnings Conference Call on Thursday, August 7, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (877) 407-6176 (US Toll-Free) +1 (201) 689-8451 (International) Live Audio Webcast: Following the live call, a replay will be available in the Investor Relations section of the Company's website at ABOUT VIEMED HEALTHCARE, INC. Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at For further information, please contact: Investor Relationsir@ Tripp SullivanSCR Partners, LLC615-942-7077 Trae FitzgeraldChief Financial OfficerViemed Healthcare, Inc.337-504-3802 SOURCE: Viemed Healthcare, Inc.
Associated Press
2 days ago
- Associated Press
Lee A. Tafoya Says Rethinking Patient-Centered Care Starts with Your Lab Partner
Why behind-the-scenes logistics, diagnostic accuracy, and ethical lab partnerships are essential to delivering truly patient-centered care, according to healthcare strategist Lee A. Tafoya. ST. LOUIS, MO / ACCESS Newswire / July 21, 2025 / In the ongoing conversation around patient-centered care, attention often gravitates toward physicians, electronic records, or bedside manner. However, Lee A. Tafoya, Business Development Executive at Midwest Innovation Laboratory, is urging healthcare professionals to look deeper into the infrastructure behind clinical decision-making. He believes that diagnostic laboratories, while rarely visible to the patient, are central to the quality of care being delivered. 'Lab work influences the majority of clinical decisions. If the system behind that data is not functioning at its best, the care delivered will inevitably fall short,' says Tafoya. With a background spanning clinical nursing, research, and leadership, Tafoya offers a rare perspective. His experience includes roles in immunology trials, stem cell apheresis, nephrology, and hospice care. Now, in laboratory business development, he works directly with facilities to improve diagnostic logistics, service responsiveness, and provider partnerships. According to him, real change in patient care starts with strengthening these foundational systems. Laboratories as Clinical Collaborators Diagnostic laboratories often operate behind the scenes, yet their output informs nearly every medical intervention. From identifying infections to confirming chronic conditions, labs provide the data that physicians rely on to act confidently and quickly. Tafoya explains that the assumption of the lab as merely a supporting service undervalues its impact. 'When labs are treated like vendors rather than clinical collaborators, important opportunities are missed. A proactive lab can help with test selection, advise on turnaround strategies, and even flag broader trends in community health,' he explains. In his current role, Tafoya works with private practices, nursing facility networks, and healthcare systems to develop service models that prioritize speed, accuracy, and relevance. He focuses not just on expanding laboratory reach but on increasing its strategic value. His work includes negotiating contracts, building targeted training programs, and supporting recovery efforts when service issues arise. Tafoya believes that involving lab partners earlier in the care planning process leads to better patient outcomes and greater efficiency across the board. Lessons from the Bedside Tafoya's insights are shaped by a career that began in clinical care. As a Registered Nurse, he provided frontline services in home health, hemodialysis, and mental health. Later, he moved into clinical trials, coordinating research in pulmonology and immunology across multiple indications, including RSV, asthma, and COVID-19 prophylaxis. His work in hematology research achieved a 100 percent success rate in Dendreon stem cell procedures. His time at the bedside taught him where breakdowns commonly occur. Delays in lab processing, unclear communication, and inconsistent test accuracy were not administrative glitches; they were obstacles with direct consequences for patient health. 'I've seen firsthand how a delayed test result can postpone critical treatment. I've also seen how fast, well-coordinated lab work can change the trajectory of a patient's recovery,' says Tafoya. These experiences inspired him to step into business development. He saw that influencing patient outcomes didn't have to stop at clinical care. Improving the systems that support providers could be just as impactful. Building Lab Partnerships Around Patient Needs Rather than promoting laboratory services based solely on cost or capacity, Tafoya focuses on alignment. He matches services to each organization's unique workflow and population needs. A rural nursing facility, for example, may require different pickup schedules or specialized testing panels than a suburban primary care clinic. 'The lab must fit into the provider's rhythm, not the other way around. When lab services adapt to the patient population and operational structure, the entire system becomes more efficient,' he notes. He also emphasizes transparency, measurable service benchmarks, and frequent communication. These efforts transform the lab from an outsourced necessity into a trusted clinical partner. In many cases, Tafoya assists in addressing legacy issues, such as long turnaround times or repeated testing errors. By implementing root cause analysis and hands-on staff training, he works to rebuild trust between providers and their lab teams. Redefining Quality in the Value-Based Era As healthcare continues to shift toward value-based care, the stakes for accuracy, timeliness, and efficiency are rising. Tafoya argues that labs should not be evaluated only on volume or price, but also on how they contribute to better patient outcomes and provider satisfaction. 'Healthcare leaders need to ask whether their lab partner is helping them meet their care goals. If they are not getting timely results, if the panels are not clinically useful, or if support is difficult to access, then the lab is holding back the entire organization,' he explains. According to Tafoya, many executives focus on the more visible aspects of care while neglecting systemic gaps in diagnostic infrastructure. That oversight can limit everything from medication accuracy to the patient's trust in their provider. To fix this, he recommends a shift in how organizations engage with lab partners. Open communication, joint planning, and shared performance metrics can help bridge the gap between back-end systems and front-line care. Personal Commitment to Innovation and Equity Beyond his professional role, Tafoya has long committed himself to underserved populations. He has volunteered with International Medical Relief, supporting clinics for Venezuelan refugees and underserved communities across the United States. There, he applied many of the same principles he advocates today: thoughtful logistics, reliable diagnostics, and patient dignity. 'Volunteering in medical relief work helped reinforce that infrastructure matters. In environments with limited access to testing, diagnosis becomes guesswork. That has a cascading effect on the care people receive,' he says. Whether working in high-tech laboratories or field-based clinics, Tafoya's approach remains grounded in compassion and clarity. He believes that no system can be truly patient-centered if it fails to include the diagnostic process in its vision. A Call to Action for Healthcare Decision-Makers Tafoya encourages healthcare executives, clinical directors, and administrators to revisit how they view their lab partnerships. He advises leaders to: 'The best labs don't just deliver results. They support better decisions, fewer complications, and stronger trust between patients and providers,' he concludes. For organizations seeking to elevate their quality of care, Tafoya's message is clear: take a closer look at your lab. It may be the most critical partner your patients never see. Media Contact: Lee A. Tafoya Business Development Executive Midwest Innovation Laboratory Email: [email protected] Phone: 314-220-8208 Website: Location: St. Louis, MO SOURCE: Lee Tafoya press release
